Adenosine monophosphate-activated protein kinase is required for pulmonary artery smooth muscle cell survival and the development of hypoxic pulmonary hypertension

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 4, 2013, Pages 609-618

  Ibe, Joyce Christina F ^a,b   Zhou, Qiyuan ^a   Chen, Tianji ^a   Tang, Haiyang ^a   Yuan, Jason X J ^a   Raj, J Usha ^a,b   Zhou, Guofei ^a  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Adenosine monophosphate activated protein kinase; Apoptosis; Autophagy; Hypoxia; Pulmonary artery smooth muscle cells

Indexed keywords

ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE ALPHA 1; ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE ALPHA 2; CASPASE 3; COMPOUND C; LACTATE DEHYDROGENASE; OXYGEN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; HUMAN PULMONARY ARTERY SMOOTH MUSCLE CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER;

ADENOSINE MONOPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANOXIA; AUTOPHAGY; CELL SURVIVAL; CELLS, CULTURED; FIBROBLASTS; HUMANS; HYPERTENSION, PULMONARY; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; PULMONARY ARTERY; PYRAZOLES; PYRIMIDINES;

EID: 84886517584     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0446OC     Document Type: Article

References (56)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
2. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119:2250-2294.
3. Walsh-SukysMC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, Verter J, Stoll BJ, Lemons JA, Papile LA, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105:14-20.
4. Durmowicz AG, Stenmark KR. Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr Rev 1999;20:e91-e102.
5. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006; 99:675-691.
6. Evans AM, Hardie DG, Peers C, Wyatt CN, Viollet B, Kumar P, Dallas ML, Ross F, Ikematsu N, Jordan HL, et al. Ion channel regulation by AMPK: the route of hypoxia-response coupling in the carotid body and pulmonary artery. Ann N Y Acad Sci 2009;1177:89-100.
7. Nagata D, Hirata Y. The role of AMP-activated protein kinase in the cardiovascular system. Hypertens Res 2010;33:22-28.
8. Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, et al. AMPK: lessons from transgenic and knockout animals. Front Biosci 2009;14: 19-44.
9. Horman S, Morel N, Vertommen D, Hussain N, Neumann D, Beauloye C, El Najjar N, Forcet C, Viollet B, Walsh MP, et al. AMP-activated protein kinase phosphorylates and desensitizes smooth muscle myosin light chain kinase. J Biol Chem 2008;283:18505-18512.
10. Evans AM, Mustard KJW, Wyatt CN, Dipp M, Kinnear NP, Hardie DG. Does AMP-activated protein kinase couple inhibition of mitochondrial oxidative phosphorylation by hypoxia to pulmonary artery constriction? Adv Exp Med Biol 2006;580:147-154.
11. Creighton J, Jian M, Sayner S, Alexeyev M, Insel PA. Adenosine monophosphate-activated kinase alpha1 promotes endothelial barrier repair. FASEB J 2011;25:3356-3365.
12. Heidrich F, Schotola H, Popov AF, Sohns C, Schuenemann J, Friedrich M, Coskun KO, von Lewinski D, Hinz J, Bauer M, et al. AMPK: activated protein kinase and its role in energy metabolism of the heart. Curr Cardiol Rev 2010;6:337-342.
13. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011;25:1895-1908.
14. Evans AM. AMP-activated protein kinase and the regulation of Ca21 signalling in O2-sensing cells. J Physiol 2006;574:113-123.
15. Gusarova GA, Trejo HE, Dada LA, Briva A, Welch LC, Hamanaka RB, Mutlu GM, Chandel NS, Prakriya M, Sznajder JI. Hypoxia leads to Na,K-ATPase downregulation via Ca(21) release-activated Ca(21) channels and AMPK activation. Mol Cell Biol 2011;31:3546-3556.
16. Mungai PT, Waypa GB, Jairaman A, Prakriya M, Dokic D, Ball MK, Schumacker PT. Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol Cell Biol 2011;31:3531-3545.
17. Mishra R, Cool BL, Laderoute KR, Foretz M, Viollet B, Simonson MS. AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem 2008;283:10461-10469.
18. Hattori Y, Akimoto K, Nishikimi T, Matsuoka H, Kasai K. Activation of AMP-activated protein kinase enhances angiotensin II-induced proliferation in cardiac fibroblasts. Hypertension 2006;47:265-270.
19. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009;8:733-741.
20. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, Taguchi T, Nakamaru K, Yano M, Kukidome D, et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005;97:837-844.
21. Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T, Hirata Y. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004;110:444-451.
22. Raghavan A, Zhou G, Zhou Q, Ibe JCF, Ramchandran R, Yang Q, Racherla H, Raychaudhuri P, Raj JU. Hypoxia-induced pulmonary arterial smooth muscle cell proliferation is controlled by Forkhead box M1. Am J Respir Cell Mol Biol 2012;46:431-436.
23. Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, Foretz M, Viollet B. 59-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006;26:5336-5347.
24. Seglen PO, Gordon PB. 3-methyladenine: specific inhibitor of autophagic/ lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci USA 1982;79:1889-1892.
25. Li J, Zeng Z, Viollet B, Ronnett GV, McCullough LD. Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke. Stroke 2007;38:2992-2999.
26. Zhao Y-Y, Zhao YD, Mirza MK, Huang JH, Potula H-HSK, Vogel SM, Brovkovych V, Yuan JXJ, Wharton J, Malik AB. Persistent ENOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 2009;119:2009-2018.
27. Ma W, Han W, Greer PA, Tuder RM, Toque HA, Wang KKW, Caldwell RW, Su Y. Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest 2011;121:4548-4566.
28. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
29. Heidari N, Hicks MA, Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 2010;1:e76.
30. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S,Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of BCL-2, in diffuse large cell lymphoma xenograft model reveal drug action on both BCL-2 and MCL-1. Clin Cancer Res 2007;13:2226-2235.
31. Hsieh Y-C, Athar M, Chaudry IH. When apoptosis meets autophagy: deciding cell fate after trauma and sepsis. Trends Mol Med 2009;15: 129-138.
32. Yen W-L, Klionsky DJ. How to live long and prosper: autophagy, mitochondria, and aging. Physiology (Bethesda) 2008;23:248-262.
33. Liang J, Shao SH, Xu Z-X, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, et al. The energy sensing LKB1-AMPK pathway regulates p27(KIP1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9: 218-224.
34. Grotemeier A, Alers S, Pfisterer SG, Paasch F, Daubrawa M, Dieterle A, Viollet B, Wesselborg S, Proikas-Cezanne T, Stork B. AMPKindependent induction of autophagy by cytosolic Ca21 increase. Cell Signal 2010;22:914-925.
35. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R, et al. Phosphorylation of ULK1 (HATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011;331:456-461.
36. Hardie DG. AMPK and autophagy get connected. EMBO J 2011;30: 634-635.
37. Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTor regulate autophagy through direct phosphorylation of ULK1. Nat Cell Biol 2011;13:132-141.
38. Chhipa RR, Wu Y, Mohler JL, Ip C. Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cell Signal 2010;22:1554-1561.
39. Vucicevic L, Misirkic M, Janjetovic K, Harhaji-Trajkovic L, Prica M, Stevanovic D, Isenovic E, Sudar E, Sumarac-Dumanovic M, Micic D, et al. AMP-activated protein kinase-dependent and-independent mechanisms underlying in vitro antiglioma action of Compound C. Biochem Pharmacol 2009;77:1684-1693.
40. Krymskaya VP, Snow J, Cesarone G, Khavin I, Goncharov DA, Lim PN, Veasey SC, Ihida-Stansbury K, Jones PL, Goncharova EA. mTor is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J 2011;25:1922-1933.
41. Zhang X, Gao R, Li J, Qi Y, Song X, Zhao L, Wang H, Pu Y, Xu K, Li J. A pharmacological activator of AMP-activated protein kinase protects hypoxic neurons in a concentration-dependent manner. Neurochem Res 2010;35:1281-1289.
42. Gusarova GA, Dada LA, Kelly AM, Brodie C, Witters LA, Chandel NS, Sznajder JI. Alpha1-AMP-activated protein kinase regulates hypoxiainduced Na,K-ATPase endocytosis via direct phosphorylation of protein kinase C zeta. Mol Cell Biol 2009;29:3455-3464.
43. Emerling BM, Weinberg F, Snyder C, Burgess Z, Mutlu GM, Viollet B, Budinger GRS, Chandel NS. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radic Biol Med 2009;46:1386-1391.
44. Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R. Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells. Anticancer Drugs 2007;18:405-410.
45. Liu C, Liang B, Wang Q, Wu J, Zou M-H. Activation of AMP-activated protein kinase alpha1 alleviates endothelial cell apoptosis by increasing the expression of anti-apoptotic proteins BCL-2 and survivin. J Biol Chem 2010;285:15346-15355.
46. Kodiha M, Rassi JG, Brown CM, Stochaj U. Localization of AMP kinase is regulated by stress, cell density, and signaling through the MEK→ERK1/2 pathway. Am J Physiol Cell Physiol 2007;293:C1427-C1436.
47. Witczak CA, Sharoff CG, Goodyear LJ. AMP-activated protein kinase in skeletal muscle: from structure and localization to its role as a master regulator of cellular metabolism. Cell Mol Life Sci 2008;65: 3737-3755.
48. Kewalramani G, Puthanveetil P, Wang F, Kim MS, Deppe S, Abrahani A, Luciani DS, Johnson JD, Rodrigues B. AMP-activated protein kinase confers protection against TNF-{alpha}-induced cardiac cell death. Cardiovasc Res 2009;84:42-53.
49. Germain M, Nguyen AP, Le Grand JN, Arbour N, Vanderluit JL, Park DS, Opferman JT, Slack RS. MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. EMBO J 2011;30: 395-407.
50. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-760.
51. Millman SE, PaganoM.MCL1 meets its end during mitotic arrest. EMBO Rep 2011;12:384-385.
52. Hamacher-Brady A, Brady NR, Gottlieb RA. Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes. J Biol Chem 2006;281:29776-29787.
53. van Suylen RJ, Aartsen WM, Smits JF, Daemen MJ. Dissociation of pulmonary vascular remodeling and right ventricular pressure in tissue angiotensin-converting enzyme-deficient mice under conditions of chronic alveolar hypoxia. Am J Respir Crit Care Med 2001;163:1241-1245.
54. Stenmark KR, McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 2005;97:95-98.
55. Emerling BM, Viollet B, Tormos KV, Chandel NS. Compound C inhibits hypoxic activation of HIF-1 independent of AMPK. FEBS Lett 2007;581:5727-5731.
56. Agard C, Rolli-Derkinderen M, Dumas-de-La-Roque E, Rio M, Sagan C, Savineau JP, Loirand G, Pacaud P. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol 2009;158:1285-1294.